TNF Pharmaceuticals Overview
Latest ROE for TNF Pharmaceuticals: -49.57% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-49.57%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for TNFA is -49.57%. That is below the sector sector average of -4.03%. Investors often review this figure alongside TNF Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, TNFA currently prints -49.57% for ROE, while the sector average sits near -4.03%. That is roughly 1131.6% below the sector mean. Large gaps often invite a closer look at TNF Pharmaceuticals's growth, margins, and balance sheet.
Return on Equity shows how effectively TNF Pharmaceuticals converts resources into returns. At -49.57%, TNFA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting TNFA's ROE (-49.57%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
